Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 23.91 Billion KRW | -25.13% |
| 2022 | 31.94 Billion KRW | 357.08% |
| 2021 | 6.98 Billion KRW | -60.38% |
| 2020 | 17.64 Billion KRW | -35.36% |
| 2019 | 27.28 Billion KRW | 14.93% |
| 2018 | 23.74 Billion KRW | 121.04% |
| 2017 | 10.74 Billion KRW | -46.93% |
| 2016 | 20.24 Billion KRW | 14.39% |
| 2015 | 17.69 Billion KRW | 12.5% |
| 2014 | 15.72 Billion KRW | 27.66% |
| 2013 | 12.32 Billion KRW | 28.15% |
| 2012 | 9.61 Billion KRW | 1.89% |
| 2011 | 9.43 Billion KRW | -20.34% |
| 2010 | 11.84 Billion KRW | 21.35% |
| 2009 | 9.76 Billion KRW | 27.22% |
| 2008 | 7.67 Billion KRW | -1.87% |
| 2007 | 7.81 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 9.24 Billion KRW | 1134.05% |
| 2024 Q2 | -765.4 Million KRW | -108.28% |
| 2023 Q3 | 5.45 Billion KRW | -32.48% |
| 2023 Q2 | 8.07 Billion KRW | -16.11% |
| 2023 Q1 | 9.63 Billion KRW | 224.84% |
| 2023 FY | 23.91 Billion KRW | -25.13% |
| 2023 Q4 | 749.45 Million KRW | -86.26% |
| 2022 Q1 | 10.5 Billion KRW | 82.74% |
| 2022 FY | 31.94 Billion KRW | 357.08% |
| 2022 Q2 | 7.4 Billion KRW | -29.54% |
| 2022 Q3 | 11.07 Billion KRW | 49.59% |
| 2022 Q4 | 2.96 Billion KRW | -73.22% |
| 2021 FY | 6.98 Billion KRW | -60.38% |
| 2021 Q1 | -8.08 Billion KRW | -468.89% |
| 2021 Q2 | 3.04 Billion KRW | 137.73% |
| 2021 Q4 | 5.74 Billion KRW | -8.35% |
| 2021 Q3 | 6.27 Billion KRW | 105.76% |
| 2020 Q1 | 7.44 Billion KRW | -13.72% |
| 2020 Q4 | 2.19 Billion KRW | -37.4% |
| 2020 Q3 | 3.49 Billion KRW | -22.42% |
| 2020 FY | 17.64 Billion KRW | -35.36% |
| 2020 Q2 | 4.51 Billion KRW | -39.38% |
| 2019 Q3 | 6.46 Billion KRW | 1.33% |
| 2019 FY | 27.28 Billion KRW | 14.93% |
| 2019 Q2 | 6.37 Billion KRW | 9.5% |
| 2019 Q4 | 8.62 Billion KRW | 33.42% |
| 2019 Q1 | 5.82 Billion KRW | -9.25% |
| 2018 Q3 | 5.15 Billion KRW | -4.6% |
| 2018 FY | 23.74 Billion KRW | 121.04% |
| 2018 Q1 | 6.77 Billion KRW | 679.55% |
| 2018 Q4 | 6.41 Billion KRW | 24.61% |
| 2018 Q2 | 5.39 Billion KRW | -20.3% |
| 2017 Q1 | 3.3 Billion KRW | -31.01% |
| 2017 Q4 | 869.03 Million KRW | -90.05% |
| 2017 FY | 10.74 Billion KRW | -46.93% |
| 2017 Q3 | 8.73 Billion KRW | 503.16% |
| 2017 Q2 | -2.16 Billion KRW | -165.58% |
| 2016 FY | 20.24 Billion KRW | 14.39% |
| 2016 Q2 | 4.33 Billion KRW | 10.76% |
| 2016 Q1 | 3.91 Billion KRW | -26.62% |
| 2016 Q3 | 7.25 Billion KRW | 67.31% |
| 2016 Q4 | 4.78 Billion KRW | -33.97% |
| 2015 FY | 17.69 Billion KRW | 12.5% |
| 2015 Q1 | 3.81 Billion KRW | -25.02% |
| 2015 Q4 | 5.33 Billion KRW | 67.85% |
| 2015 Q3 | 3.17 Billion KRW | -40.75% |
| 2015 Q2 | 5.36 Billion KRW | 40.46% |
| 2014 Q2 | 3.05 Billion KRW | 35.08% |
| 2014 Q1 | 2.26 Billion KRW | -35.54% |
| 2014 FY | 15.72 Billion KRW | 27.66% |
| 2014 Q4 | 5.09 Billion KRW | -4.28% |
| 2014 Q3 | 5.32 Billion KRW | 74.21% |
| 2013 Q2 | 3.7 Billion KRW | 89.2% |
| 2013 Q3 | 3.15 Billion KRW | -14.81% |
| 2013 Q4 | 3.5 Billion KRW | 11.21% |
| 2013 FY | 12.32 Billion KRW | 28.15% |
| 2013 Q1 | 1.95 Billion KRW | -42.38% |
| 2012 Q3 | 2.22 Billion KRW | -5.57% |
| 2012 Q4 | 3.39 Billion KRW | 52.62% |
| 2012 FY | 9.61 Billion KRW | 1.89% |
| 2012 Q1 | 1.47 Billion KRW | 0.0% |
| 2012 Q2 | 2.35 Billion KRW | 59.44% |
| 2011 Q1 | 3.32 Billion KRW | 485.51% |
| 2011 Q2 | 3.07 Billion KRW | -7.37% |
| 2011 Q3 | 2.08 Billion KRW | -32.15% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 9.43 Billion KRW | -20.34% |
| 2010 Q2 | 3.64 Billion KRW | -21.43% |
| 2010 Q1 | 4.63 Billion KRW | 90.21% |
| 2010 FY | 11.84 Billion KRW | 21.35% |
| 2010 Q3 | 4.43 Billion KRW | 21.81% |
| 2010 Q4 | -861.45 Million KRW | -119.43% |
| 2009 Q4 | 2.43 Billion KRW | -3.44% |
| 2009 FY | 9.76 Billion KRW | 27.22% |
| 2009 Q3 | 2.52 Billion KRW | -5.22% |
| 2009 Q2 | 2.66 Billion KRW | 24.28% |
| 2009 Q1 | 2.14 Billion KRW | 2.38% |
| 2008 Q3 | 1.2 Billion KRW | -47.27% |
| 2008 Q2 | 2.27 Billion KRW | 8.16% |
| 2008 Q1 | 2.1 Billion KRW | 22.62% |
| 2008 FY | 7.67 Billion KRW | -1.87% |
| 2008 Q4 | 2.09 Billion KRW | 74.26% |
| 2007 FY | 7.81 Billion KRW | 0.0% |
| 2007 Q4 | 1.71 Billion KRW | -20.76% |
| 2007 Q3 | 2.16 Billion KRW | 13.3% |
| 2007 Q2 | 1.91 Billion KRW | -5.61% |
| 2007 Q1 | 2.02 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 433.063% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 58.756% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 140.138% |
| HANDOK Inc. | -28.79 Billion KRW | 183.052% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 384.212% |
| Yuhan Corporation | 93.5 Billion KRW | 74.423% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -115.033% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 196.393% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 83.644% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -581.664% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1054.229% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1253.229% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 628.57% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -7.093% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 433.063% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 214.212% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -567.442% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 120.222% |
| JW Holdings Corporation | 19.02 Billion KRW | -25.705% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 130.302% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 88.746% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 35.371% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 141.721% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -290.687% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -1337.713% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -377.885% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 433.063% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 35.299% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 78.55% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 35.371% |
| Yuhan Corporation | 93.5 Billion KRW | 74.423% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 247.183% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 717.125% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -290.849% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 35.371% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -26.506% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 50.443% |
| CKD Bio Corp. | -24.19 Billion KRW | 198.861% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 12.834% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 19.673% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 141.721% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 49.121% |
| Boryung Corporation | 40.2 Billion KRW | 40.509% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 176.34% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1054.229% |
| JW Lifescience Corporation | 28.14 Billion KRW | 15.019% |